Randy Hall's study: GPR37L1's role in shaping cortical astrocytes during development Dr. From Indivior In Extended Substance Use Disorder Research Collaboration Addex Therapeutics To Release Half-Year 2023 Financial Results And Host Conference Call On August 10, 2023 X4 Pharmaceuticals Closes $115 Million hand Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half

August 2022 "We are happy to announce you our 2nd IRN i-GPCRnet meeting that will be held at the University of Wurzburg (Germany) from september 30th to october 1rst." Read more at the source #DrGPCR #GPCR #IndustryNews

August 2022 "Join Us in Boston for Discovery On Target 2022! Discovery on Target (DOT) highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics to small molecules." Read more at the source #DrGPCR #GPCR #IndustryNews

August 2022 "GPCRs in Medicinal Chemistry Event 8th RSC / SCI symposium on GPCRs in Medicinal Chemistry Dates Wednesday-Friday, 5th-7th October 2022 Place Evotec Campus Levi-Montalcini, Verona, Italy Downloads and Links Registration closing dates: 6th September – registration against invoice (bank transfers): Tuesday, 6th September 30th September – online registration (card payments)" Read more at the source #DrGPCR #GPCR #IndustryNews

August 2022 "WELCOME 4GPCRnet meeting bringing together four of the biggest GPCR networks in Europe for a joint meeting in Leipzig. Four of the biggest European networks on GPCR research (COST Actions Adher’n Rise and ERNEST plus DFG-funded SFB1423 and FOR2372) have joined forces to organize an international meeting, which will take place from 26th-29th September 2022 in the beautiful city of Leipzig in Germany. We aim to connect renowned international experts of the field with early career ‘rising stars’. The event will take place in the heart of Leipzig, which offers a colorful mixture of culture and vivid social life." Read more at the source #DrGPCR #GPCR #IndustryNews

August 2022 RAB-Symposium - Regulatory Autoantibodies Targeting GPCRs. September 15-16, 2022. Lübeck, Germany. Hybrid meeting. "Dear Sir or Madam, dear Colleagues, It gives me great pleasure to announce the fourth hybrid symposium on regulatory autoantibodies targeting G-protein-coupled receptors (GPCRs) in Lübeck. GPCRs are involved in a variety of physiological and pathophysiological processes. So far, numerous therapeutics targeting GPCRs have been developed, with a focus on small molecules and monoclonal antibodies for the treatment of cancer, infections, metabolic disorders or inflammatory diseases. Recently, functional autoantibodies targeting GPCRs have been associated with various disease-specific manifestations, highlighting a potential new area for therapeutic intervention. Therefore, the aim of this symposium is to bring together the current knowledge on the role of autoantibodies targeting GPCRs in various diseases, such as cardiovascular diseases, renal diseases, autoimmune diseases such as systemic sclerosis or systemic lupus erythematosus. In addition, one aim is to bring together the mode of action of autoantibodies in immune regulation and pathogenesis." Read more at the source #DrGPCR #GPCR #IndustryNews

Bursicon receptor gene HLGR2 as a potential RNA interference target for control of the fall webworm Hyphantria

pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its half-year

March 2022 "Geneva, Switzerland, March 7, 2022 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it will issue its full-year 2021 financial results on Thursday, March 10, 2022. Tim Dyer, CEO, Roger Mills, CMO and Robert Lütjens, Head of Discovery Biology, will provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 GMT / 10:00 EST / 07:00 PST) the same day. " Read more at the source #DrGPCR #GPCR #IndustryNews

Did you register for our next Dr. GPCR Virtual Cafe? Register today! Addgene's Dr. Joanne Kamens is our guest. If you need a plasmid for your research or you want to share your materials, this is the place to go. https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe/ #gpcr #drgpcr #virtualcafe #addgene

The all-atom MD simulations reveal that CBD induces conformational changes linked with agonist-bound

October 2022 "Psychedelics, also known as classical hallucinogens, affect processes related to perception

Read more at the source #DrGPCR #GPCR #IndustryNews 5-HT2AR, GPCR, hallucinogens, in vitro assay, psychedelics

August 2022 "Psychedelic research across different disciplines and biological levels is growing at a remarkably fast pace. In the prospect of a psychedelic drug becoming again an approved treatment, much of these efforts have been oriented toward exploring the relationship between the actual psychedelic effects and those manifestations of therapeutic interest. Considering the central role of the serotonin 5-HT2A receptor in the distinct effects of psychedelics in human psyche, neuropharmacology sits at the center of this debate and exploratory continuum. Here we discuss some of the most recent findings in human studies and contextualize them considering previous preclinical models studying phenomena related to synaptic plasticity. A special emphasis is placed on knowledge gaps, challenges, and limitations to evaluate the underpinnings of psychedelics' potential antidepressant action." Read more at the source #DrGPCR #GPCR #IndustryNews

., University of California, San Diego and Rady Children's Hospital, San Diego on June 13 from 11:00 company also presented data highlighting patient preferences and treatment patterns in classic CAH in Hall

Progresses Its GLP-1 Receptor Agonist PF-06954522 into a Phase 1 Trial Andrew Hopkins Inducted into RSC BMCS Hall

All-Atom Molecular Dynamics Simulations Indicated the Involvement of a Conserved Polar Signaling Channel Slow-rising and fast-falling dopaminergic dynamics jointly adjust negative prediction error in the ventral understanding of the role of muscarinic receptors in the molecular pathology and treatment of schizophrenia Call

with cannabis, but John Streicher, PhD, takes a closer look at the plant’s aromatic chemical compounds called

Topline results from 40 subjects are expected in the second half of the calendar year."

All the above lightly represent the potential applications of Nbs to facilitate the development of more Tailorable half-life: Nanobodies can extend their half-life through PEGylation or fusion to serum albumin This allows for tailoring the half-life of nanobodies to increase their therapeutic window depending

disease therapy Primary cilia in skeletal development and disease Industry News Addex Reports 2023 Half Trial with Cancer Immunotherapy Drug HTL0039732 Exscientia Business Update for Second Quarter and First Half

GPR110 belongs to adhesion GPCR and was the functional receptor of N-docosahexaenoyl ethanolamine (also called

Thus, we call them gluopsins.

Sotrovimab is the first monoclonal antibody showing preclinical efficacy against all COVID-19 variants , including the delta and omicron mutations, Vir CEO George Scangos said on a Dec. 7 call with analysts

One successful strategy is the so-called metabolic surgery whose beneficial effects are beyond dietary

its high chemoresistance and the presence of a cell subpopulation that persists under hypoxic niches, called

., 1950 ), also called Duffy-antigen/receptor for chemokines, or DARC ( Novitzky-Basso and Rot, 2012

Interface from Molecular Dynamics Simulations and Quantum Chemical Calculations "Allosteric modulators are called raises many questions about the ligand interactions and stability, the binding site structure, and how all